Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

by · The Markets Daily

Research analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN – Get Free Report) in a research note issued on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital lowered their price target on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a report on Friday, August 23rd.

Read Our Latest Report on EVGN

Evogene Stock Performance

EVGN opened at $1.35 on Friday. Evogene has a 1-year low of $1.20 and a 1-year high of $10.40. The company has a 50-day moving average of $1.86 and a 200-day moving average of $3.61. The company has a market capitalization of $7.24 million, a P/E ratio of -0.30 and a beta of 1.36.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

(Get Free Report)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.

See Also